Methylation of ctDNA can also be used to monitor tumor burden and evaluate the therapeutic response of patients [171,172], correlating better than classical biomarkers such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)-19-9. Here, CEACAM5 is linked to neoplasm.